Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 5/20 | 0.68 |
| ▸ | KAT2A | Q92830 | 4/20 | 0.68 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.68 |
| ▸ | CASP3 | P42574 | 4/20 | 0.63 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12179299 | 0.85 | CASP3 (0.65) | G6PDKAT2AKAT2BCASP3 | |
| SCHEMBL12205847 | 0.85 | G6PD (0.62) | G6PDKAT2AKAT2BCASP3 | |
| SCHEMBL12230845 | 0.84 | KAT2A (0.70) | G6PDKAT2AKAT2BCASP3 | |
| SCHEMBL9886495 | 0.82 | DTYMK (0.74) | G6PDKAT2AKAT2BCASP3 | |
| SCHEMBL19240713 | 0.82 | CASP3 (0.66) | G6PDKAT2AKAT2BCASP3FAAH | |
| SCHEMBL13606221 | 0.82 | G6PD (0.72) | G6PDKAT2AKAT2BCASP3 | |
| SCHEMBL9274624 | 0.81 | KAT2A (0.66) | G6PDKAT2AKAT2BCASP3 | |
| SCHEMBL12370925 | 0.81 | KAT2A (0.67) | G6PDKAT2AKAT2BCASP3 | |
| SCHEMBL20937506 | 0.81 | CASP3 (0.59) | G6PDKAT2AKAT2BCASP3 | |
| SCHEMBL12230840 | 0.81 | KAT2A (0.71) | G6PDKAT2AKAT2BCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108115-A1 | ENHANCED PRODUCTION OF TAXOL AND TAXANES BY CELL CULTURES OF TAXUS SPECIES | DFB BIOTECH, INCORPORATED (US) | 2008-05-08 | — | — | US | claimed |
| US-7294642-B2 | 1,3-Diamino-2-hydroxypropane pro-drug derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-13 | — | — | US | claimed |
| US-7264951-B1 | Enhanced production of taxol and taxanes by cell cultures of Taxus species | PHYTON, INC. (US) | 2007-09-04 | — | — | US | claimed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-109535153-B | Benzisothiazolinone isoxazole acetamide derivative and synthetic method and application thereof | 南京工业大学 | 2020-07-17 | — | — | CN | disclosed |
| WO-2020020101-A1 | BENZISOSELENAZOLIDONE AMINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海星叶医药科技有限公司 | 2020-01-30 | — | — | WO | disclosed |
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2019-09-19 | — | — | US | disclosed |
| EP-3483167-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-3013337-B1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC (US) | 2018-10-31 | — | — | EP | disclosed |
| CN-103772377-B | 1,3, 4-thiadiazole benzisothiazolinone acetamide derivative and synthetic method thereof | NANJING TECH UNIVERSITY (CN) | 2016-04-13 | — | — | CN | disclosed |
| US-9278982-B2 | Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells | NATIONAL YANG-MING UNIVERSITY (TW) | 2016-03-08 | — | — | US | disclosed |
| EP-0828488-B1 | ISOTHIAZOLONES | WARNER LAMBERT CO (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6133270-A | Isothiazolones and pharmaceutical formulations | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| US-6001863-A | USEFUL AS ANTIVIRAL, ANTIINFLAMMATORY AND ANTIATHEROSCLEROSIS AGENT; ADMINISTERING TO THE PATIENT IN NEED OF ZINC EJECTION FROM NUCLEOCAPSID PROTEIN | WARNER-LAMBERT COMPANY (US) | 1999-12-14 | — | — | US | disclosed |
| US-5889034-A | ANTIINFLAMMATORY AGENT; ANTIATHEROSCLEROSIS AGENT; VIRICIDES | WARNER-LAMBERT COMPANY (US) | 1999-03-30 | — | — | US | disclosed |
| CN-1185737-A | Isothiazolones | WARNER LAMBERT CO (US) | 1998-06-24 | — | — | CN | disclosed |
| US-5733921-A | ANTIRETROVIRAL AGENTS; ANTIINFLAMMATORY AGENTS; ANTIATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5668162-A | Isothiazolones lower plasma levels of lipoprotein(a) | WARNER-LAMBERT COMPANY | 1997-09-16 | — | — | US | disclosed |
| US-5620997-A | VIRICIDES, ANTIINFLAMMATORY AGENTS, ANTIATHEROSCLEROTIC AGENT | WARNER-LAMBERT COMPANY (US) | 1997-04-15 | — | — | US | disclosed |
| US-3960856-A | Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2H-1,2-benzothiazine 1,1-dioxide | WARNER-LAMBERT COMPANY (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284135-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | G6PD 750/4885KAT2A 1296/4885KAT2B 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.